Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-06
2006-06-06
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S400000, C514S254020, C514S427000
Reexamination Certificate
active
07056938
ABSTRACT:
Upon exposure to UVB, the epidermal component trans-urocanic acid is not only photoisomerized into cis-urocanic acid, but will also, at least in part, be photooxidized into urocanic acid oxidation products. We hypothesized that urocanic acid oxidation products can mimic UV-induced systemic immunosuppression comparable to the suppressive properties already established for cis-urocanic acid. A crude mixture of urocanic acid oxidation products showed a significant suppression of the sensitization phase of the systemic contact hypersensitivity response to picryl chloride. Three of the urocanic acid oxidation products were selected for this study: imidazole-4-carboxylic acid, imidazole-4-carboxaldehyde and imidazole-4-acetic acid. Effects on the sensitization-, elicitation- and post-elicitation phase of contact hypersensitivity to picryl chloride in BALB/c mice were studied and compared to the effects of cis-urocanic acid. Imidazole-4-carboxaldehyde was equally effective at suppressing the sensitization phase as cis-urocanic acid. The triplet combination of the imidazoles showed more pronounced suppression than that induced by cis-urocanic acid. The most effective compounds for the suppression of the elicitation phase appeared to be imidazole-4-acetic acid and cis-urocanic acid. Significant suppression of the post-elicitation phase was only obtained with the triplet combination of imidazole-4-carboxaldehyde, imidazole-4-carboxylic acid and imidazole-4-acetic acid, which combination appeared to be effective at all three tested phases, Because these three urocanic acid oxidation products are present in UVB-exposed human stratum corneum, these compounds may play a role in UVB-induced immunosuppression.
REFERENCES:
patent: 3515789 (1970-06-01), Roberts
patent: 5723482 (1998-03-01), Degwert et al.
patent: 6133318 (2000-10-01), Hart
patent: 6281244 (2001-08-01), Schneider et al.
“Oxidative Breakdown and Conversion of Urocanic Acid Isomers by Hydroxyl Radical Generating Systems”, Kammeyer et al., Biochimica et Biophysica Acta 1526, 2001, 277-285.
“The Effect of Urocanic Acid on Graft Rejection in an Experimental Model of Orthotopic Corneal Transplantation in Rabbits”, Fikipec et al., Graefe's Archive for Clinical and Experimental Ophthamology, 1998, 236(1), 65-68.
“Oxidative Conversion of Trans- and Cis-Urocanic Acid by Hydroxyl Radicals and the Identification of Oxidation Products”, Kammeyer et al., abstract, International Congress on Photobiology, 2000.
L-Glycine: A Novel Antiinflammatory, Immunomodulatory, and Cytoprotective Agent, Zhong et al., abstract, Current Opinion in Clinical Nutrition and Metabolic Care, 6(2):229-240, 2003.
Bos Joannes Dositheus
Kammeijer Arthur
Academisch Ziekenhuis Bij De Univ.
Cooper & Dunham LLP
Kwoon Brian S.
Low Christopher S. F.
LandOfFree
Method for scavenging radicals with urocanic acid,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for scavenging radicals with urocanic acid,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for scavenging radicals with urocanic acid,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619828